Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. FL BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination FL
News/Events
Local FL News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
News
 Local FL News
 Submit News Release
 Calendar
 Submit Event
 CEO Reading
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad:  Every Child Deserves a Chance to Play Baseball
Facilities
 
Advertising
 

NEW University of Washington Basic Bioscience Certificate starts Jan 2009

UW M.S. in Biomedical Regulatory Affairs with evening classes for working professionals


Medchem Source

Local News

Submit News Release


Search Articles: 

  • Monsanto Company completes acquisitions of CanaVialis and Alellyx  Monsanto announced that it has completed its proposed acquisition of Aly Participacoes, which operates the sugarcane breeding and technology companies, CanaVialis and Alellyx, both of which are based in Brazil.
    Monsanto Company December 02, 2008  
  • AIDS vaccine trials enter second phase  An Atlanta-based biotech company announced —- on World AIDS Day —- that it is launching the second phase of trials for its vaccine to prevent AIDS. The trials for the GeoVax Labs vaccine will occur at 12 clinical sites, in collaboration with the NIH and the HIV Vaccine Trials Network.
    Atlanta Journal-Constitution December 02, 2008  Andy Miller
  • Monsanto to leverage its technology to enhance yield and economic value for farmers  As farmers in the U.S. are making their initial seed purchase decisions for the 2009 growing season, Monsanto Company plans to discuss the reasons behind its confidence that it can make good on its commitment to more than double its fiscal 2007 gross profit by 2012.
    Monsanto Company December 02, 2008  
  • GSK and Theravance announce positive phase 2b results for LABA, `444  GlaxoSmithKline and Theravance announced positive results from the phase 2b study of the novel, long-acting beta agonist (LABA) GW642444 (‘444) in patients with moderate to severe asthma.
    GlaxoSmithKline December 02, 2008  
  • ETHICON completes divestiture of Professional Wound Care Business to One Equity Partners  ETHICON, a Johnson & Johnson company, announced that it has completed the divestiture of its Professional Wound Care business to One Equity Partners. Financial terms of the transaction are not being disclosed.
    Johnson & Johnson December 01, 2008  
  • Cardinal Health, SRI Surgical sign five-year agreement for surgical kits  Cardinal Health and SRI/Surgical Express announced a five-year supply and co-marketing agreement to offer surgical kits that include disposable health care products from Cardinal Health and reusable health care products from SRI Surgical.
    Cardinal Health December 01, 2008  
  • Johnson & Johnson announces definitive agreement to acquire Mentor  Johnson & Johnson and Mentor Corporation, a leading supplier of medical products for the global aesthetic market, announced a definitive agreement whereby Mentor will be acquired for approximately $1.07 billion in a cash tender offer.
    Johnson & Johnson December 01, 2008  
  • Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain  Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.
    Eli Lilly and Company November 28, 2008  
  • MedImmune receives FDA Complete Response letter on motavizumab  AstraZeneca announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab.
    AstraZeneca November 28, 2008  
  • Wyeth and Progenics announce positive outcome of Phase 3 study of subcutaneous RELISTOR  Wyeth Pharmaceuticals and Progenics Pharmaceuticals announced that a phase 3 clinical study investigating RELISTOR(R) subcutaneous injection to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain achieved statistical significance for the primary endpoints.
    Progenics Pharmaceuticals, Inc. November 26, 2008  

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2008 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

FloridaLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of Florida.